Sofinnova Partners Raises €472 ($548) Million to Form Largest Early-Stage Healthcare VC Fund in Europe


European task capital firm has raised €1 billion inside the last twelve months across its expanding lifestyles technological know-how investment platform

Sofinnova Partners, a main European life sciences mission capital firm primarily based in Paris, London and Milan, announced today the near of its today’s early-stage healthcare mission capital fund, Sofinnova Capital X, oversubscribed at €472 ($548) million. This brings the whole quantity the VC has raised to €1 billion within the last twelve months throughout its multi-fund platform, and the total AUM to over €2.Five billion. Capital X, the 10th new release of Sofinnova Partners’ flagship fund, is the largest healthcare fund dedicated to early-level investments and enterprise creation in Europe.

Sofinnova Partners Raises

Sofinnova Capital X will make investments within the most promising biopharmaceutical and clinical tool begin-u.S.A.That cope with urgent unmet medical needs and intention to transform sufferers’ lives. In preserving with the contemporary strategy, the group will source and create fee across a portfolio of groundbreaking improvements in healthcare, assisting marketers globally within the introduction and increase of their businesses.

Capital X become effectively raised with institutional buyers which include pension budget, insurance groups, foundations, endowments, company investors, and prominent family places of work from throughout Europe, Asia, and North America. The Fund welcomed returned present traders and attracted new blue chip confined partners, reflecting sustained confidence inside the firm’s ability to generate strong economic returns.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, stated: “The near of Capital X, significantly oversubscribed and raised in report time, comes at a pivotal second as the significance of healthcare innovation has turn out to be distinctly clean to all. The reality we were capable of improve €1 billion throughout our platform over the past three hundred and sixty five days is a tribute to our investors and their conviction in our capacity to strengthen our leading function in Europe.”

Henrijette Richter, Managing Partner of Sofinnova Partners, stated: “We are thrilled to have raised the biggest fund devoted to early-level healthcare investments in Europe. This is an vital milestone for Sofinnova Partners. Capital X will permit us to leverage over 30 years of cumulative experience perfecting this method. We now have greater capital than ever to manual main marketers as they launch new companies to growth groundbreaking treatment options which have the potential to change peoples’ lives.”


Sofinnova Partners Raises €472 ($548) Million to Form Largest

Clifford Chance acted as felony recommend and Triago as placement agent.

About Sofinnova Partners

Sofinnova Partners is a main European undertaking capital firm in existence sciences, focusing on healthcare and sustainability. Based in Paris, London and Milan, the business enterprise brings collectively a team of professionals from anywhere inside the global with strong medical, scientific and organization statistics. Sofinnova Partners is a palms-on enterprise builder for the duration of the entire fee chain of lifestyles sciences investments, from seed to later-degree. The enterprise actively companions with ambitious marketers as a lead or cornerstone investor to expand transformative innovations which have the capability to surely impact our collective future.

Founded in 1972, Sofinnova Partners is a deeply-set up venture capital company in Europe, with 50 years of enjoy backing over 500 businesses and growing market leaders around the world. Today, Sofinnova Partners has over €2.Five billion underneath management.

Recent Post

More Better Leads Forever Part 4

More Better Leads Forever Part 4 B2B product marketing in a rapidly changing world Product marketing used to be straightforward – generate more, better-quality leads to pass on to sales.

Read More »


OUTSOURCE & FORTIFY 2023 was a major downshift for publishers compared to the previous year, when they saw record CPMs and a surge in demand coming out of the COVID-19

Read More »